Literature DB >> 14654222

Cycloserine and threo-dihydrosphingosine inhibit TNF-alpha-induced cytotoxicity: evidence for the importance of de novo ceramide synthesis in TNF-alpha signaling.

Sybille G E Meyer1, Herbert de Groot.   

Abstract

Measuring the cell death induced by tumor necrosis factor (TNF-alpha) in L929 cells, we discovered for the first time that L-cycloserine, an established inhibitor of serine palmitoyltransferase, as well as DL-threo-dihydrosphingosine (threo-DHS, threo-sphinganine) significantly protected against TNF-alpha-induced cytotoxicity. Under the same conditions sphingosine and DL-erythro-dihydrosphingosine (erythro-DHS) did not change TNF-alpha-induced cytotoxicity, thus underlining the specificity of threo-DHS. In serine-labeled cells, newly (de novo) synthetized labeled ceramide was significantly diminished by threo-DHS alone or together with TNF-alpha, which makes the (dihydro) ceramide synthase the likely target of threo-DHS. These results suggest the decisive role of ceramide de novo synthesis in TNF signaling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654222     DOI: 10.1016/j.bbamcr.2003.10.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Neutral sphingomyelinase activation precedes NADPH oxidase-dependent damage in neurons exposed to the proinflammatory cytokine tumor necrosis factor-α.

Authors:  Brian M Barth; Sally J Gustafson; Thomas B Kuhn
Journal:  J Neurosci Res       Date:  2011-09-19       Impact factor: 4.164

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

Review 3.  A role for sphingolipids in the pathophysiology of obesity-induced inflammation.

Authors:  Benjamin T Bikman
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

4.  Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.

Authors:  Lawrence G Miller; Jennifer A Young; Swapan K Ray; Guanghu Wang; Sharad Purohit; Naren L Banik; Somsankar Dasgupta
Journal:  Neurochem Res       Date:  2017-05-05       Impact factor: 3.996

5.  You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

Authors:  Joseph V Varre; William L Holland; Scott A Summers
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-23       Impact factor: 5.228

Review 6.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

7.  Inhibition of de novo ceramide biosynthesis affects aging phenotype in an in vitro model of neuronal senescence.

Authors:  Alberto Granzotto; Manuela Bomba; Vanessa Castelli; Riccardo Navarra; Noemi Massetti; Marco d'Aurora; Marco Onofrj; Ilaria Cicalini; Piero Del Boccio; Valentina Gatta; Annamaria Cimini; Daniele Piomelli; Stefano L Sensi
Journal:  Aging (Albany NY)       Date:  2019-08-29       Impact factor: 5.682

Review 8.  Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease.

Authors:  Bhagirath Chaurasia; Chad Lamar Talbot; Scott A Summers
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

Review 9.  Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease.

Authors:  Melania Gaggini; Rudina Ndreu; Elena Michelucci; Silvia Rocchiccioli; Cristina Vassalle
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 10.  Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces.

Authors:  Loubna Abdel Hadi; Clara Di Vito; Laura Riboni
Journal:  Mediators Inflamm       Date:  2016-01-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.